Article

Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible Documentation

2020-03-08

Abstract excerpt

<h4>Introduction</h4> The Cancer Drugs Fund (CDF) was reformed in 2016 with an ambition to generate new evidence on effectiveness, and to review existing drugs in the fund. We set out to evaluate: whether drugs transitioning from the old CDF were re-reviewed as planned; whether new drugs have a “data collection arrangement” (DCA) as planned; and whether evidence generated under the DCA using routine data from the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b33d63a9-da91-561e-98be-fa4cf7840111
DOI: 10.1101/2020.03.06.19014944

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationDOI 10.1101/2020.03.06.19014944Read

Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity Read

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024Semantic proximity Read

The Template, Not the Exception: Ojemda and the Self‐Confirming Logic of the Joint Clinical AssessmentSemantic proximity Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

Data quality as the missing translational layer in computational drug repurposingSemantic proximity Read

Global mapping of randomised trials related articles published in high-impact factor medical journals: a cross-sectional analysisSemantic proximity Read

Real World Evidence – Current Developments and PerspectivesSemantic proximity Read

The Current Landscape of Clinical TrialsSemantic proximity Read